Personalis Receives Medicare Coverage for NeXT Personal in Lung Cancer Surveillance
The NeXT Personal molecular residual disease test can now be used for surveillance of patients with Stage I to III non-small cell lung cancer.
Tag: non-small cell lung cancer
All
Latest
All
Latest
Liquid Biopsy May Identify NSCLC Patients Who Will Benefit from Radiation
A novel liquid biopsy test may determine which patients with NSCLC that has spread beyond the lungs will benefit from high-dose radiation.
All
Latest
FDA Approves Agilent’s NSCLC Liquid Biopsy Companion Diagnostic Test
Agilent Technologies announced that the FDA has approved the ctDx FIRST as a companion diagnostic to identify advanced NSCLC.
Blood Drops May Help Detect Early-Stage Lung Cancer
A study shows proof-of-concept of using a drop of blood to reveal lung cancer, which may help diagnose early-stage lung cancer in asymptomatic patients.
Read More
FDA Approves Thermo Fisher’s Test to Identify Therapies for Non-Small Cell Lung Cancer Patients
Thermo Fisher’s companion diagnostic test to identify targeted therapies for non-small cell lung cancer patients was granted premarket approval by the FDA.
Read More
Quest Diagnostics Offers New Liquid Biopsy Lung Cancer Test
Biocept’s liquid biopsy-based Target Selector NGS Lung Panel test aids genomic profiling in patients with advanced non-small cell lung cancer (NSCLC).
Read More
Biodesix Announces Liquid Biopsy NGS Test with 72-Hour Turnaround
The study showed that the rapid liquid biopsy NGS test was able to accurately detect actionable genomic alterations in patients with NSCLC with a turnaround time of only 72 hours.
Read More
FDA Approves First CDx for Expanded EGFR TKI Therapies in NSCLC Patients
The group claim will also enable the test to be used as a CDx for any future approved EGFR TKI therapies targeting the same mutations.
Read More
Large Prospective Lung Cancer Study to Be Presented at ESMO
Idylla reduced EGFR mutation testing turnaround time by more than a week versus reference methods for patients with NSCLC.
Read More
FDA Approves First NGS-Based CDx for RET Fusion-Positive NSCLC
Thermo Fisher Scientific’s Oncomine Dx Target Test simultaneously evaluates 23 genes clinically associated with NSCLC.
Read More
Thermo Fisher, Hengrui Therapeutics to Develop CDx for NSCLC
The companion diagnostic will leverage the Oncomine Precision Assay to identify non-small cell lung cancer patients with HER2 mutations.
Read More
Israel Expands Non-Small Cell Lung Cancer Testing Coverage
Israeli laboratories are approved to use molecular profiling assays for NSCLC patients using Thermo Fisher Scientific’s Oncomine Comprehensive Assay Plus.
Read MoreGuardant Health, Janssen to Develop Liquid Biopsy Companion Diagnostic
The collaborators are pursuing regulatory approval of the Guardant360 CDx as a companion diagnostic for amivantamab for the treatment of NSCLC.
Read MoreNeoGenomics and Inivata Collaborate to Commercialize InVisionFirst-Lung Liquid Biopsy Test
InVisionFirst-Lung is a ctDNA next-generation sequencing liquid biopsy assay testing 37 genes relevant to the care of advanced NSCLC patients.
Read More
Thermo Fisher Scientific Signs Agreement with Janssen to Codevelop Companion Diagnostic for Cancer
Thermo Fisher Scientific will collaborate with Janssen scientists to validate multiple biomarkers, which will be used to identify variant-positive patients for enrollment into clinical trials focused on non-small cell lung cancer.
Read More
Navify Guidelines App Offers Clinicians Guidance for Patients with Common Cancers
The Navify guidelines app pulls the latest clinical guidance for breast, colorectal, non-small cell lung, and prostate cancers from the National Comprehensive Cancer Network.
Read More
Decision Expands Guardant360 Coverage to Most Solid Tumor Types
The draft LCD applies to advanced cancer patients who are covered by Medicare for next-generation sequencing of tumor tissue, but have insufficient or unavailable tissue samples.
Read More
Multivariate Blood Test Can Predict Outcomes for Non-Small Cell Lung Cancer
Individuals identified with VeriStrat poor results had significantly lower overall survival when treated with immune checkpoint inhibitor-based regimens.
Read More